mRNA/saRNA Manufacturing RNA Synthesis Process & Methods

Aldevron Chief Scientific Officer, Venkata Indurthi, Ph.D., shared his knowledge and experience with manufacturing RNA in a webinar entitled, “mRNA/saRNA Manufacturing – Considerations to Accelerate the Path to Clinic.” As a follow up, Dr. Indurthi sat down with Communications Sr. Director, Ellen Shafer, for an interview to answer dozens of questions he received during the presentation.

Dr. Indurthi discusses key considerations for RNA synthesis processes and methods and their impact on downstream production. RNA optimization does not rely on a set of protocols; rather, it is unique to each application. Therapeutic programs require a much higher purity than RNA molecules used in vaccine applications, for example. While the RNA modality is the same for each application, therapeutics will require a much purer molecule. Developing a capping technique will also need to be tailored to fit the manufacturing needs of specific project. Both enzymatic capping and co-transcriptional capping can get you to the same final RNA, but your enzyme engineering capabilities and raw materials security supply could make one option more beneficial from a manufacturing standpoint.

Optimizing elements such as purification, capping, and tailing methods is essential to reduce pressure on downstream production. Learn more about messenger RNA (mRNA) and self-amplifying RNA (saRNA) development, validation, and manufacturing processes and how different projects' needs may vary.